Y mAbs Therapeutics (YMAB) — Strategic Asset Allocation Index
Y mAbs Therapeutics (YMAB) has a Strategic Asset Allocation Index of 0.4% as of June 2023. Strategic assets (PP&E of $375.00K plus long-term investments of $-) total $375.00K, measured against net assets of $104.68 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Y mAbs Therapeutics Strategic Asset Allocation Index (2018–2022)
This chart shows how Y mAbs Therapeutics's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of June 2023, the index stands at 0.4%, representing strategic assets of $375.00K against net assets of $104.68 Million USD. Explore Y mAbs Therapeutics operating cash flow efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Y mAbs Therapeutics (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Y mAbs Therapeutics from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see YMAB company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 2.1% | $2.34 Million | $2.34 Million | $- | $109.22 Million | ▼ -1.0 pp |
| 2021 | 3.2% | $5.69 Million | $5.69 Million | $- | $180.11 Million | ▲ +1.4 pp |
| 2020 | 1.7% | $1.82 Million | $1.82 Million | $- | $105.84 Million | ▼ -0.3 pp |
| 2019 | 2.0% | $4.04 Million | $4.04 Million | $- | $198.90 Million | ▲ +1.9 pp |
| 2018 | 0.1% | $205.00K | $205.00K | $- | $140.53 Million | — |